Shinhan Square Bridge (S2 Bridge) Incheon is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub.
S2 Bridge is located in Songdo, a city in South Korea recognized as a global business center and bio-cluster. Key partnering organizations include Shinhan Financial Group, a leading global financial group that supports an innovative investment ecosystem, and Celltrion, a global biotech company that supports open innovation opportunities to accelerate promising biotech startups, and Incheon Metropolitan City that actively helps to accelerate the local biotech infrastructure. From the seed to global expansion stage, S2 Bridge focuses on accelerating life science startups based on their innovative technologies.
Shinhan Financial Group has created S² Bridge as a platform to accelerate start-up companies in major Korean cities like Seoul, Incheon, Jeju, and Daegu.
With the motto of “One Place, One Platform”, 『Shinhan Square Bridge (S2 Bridge) Incheon is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub.
S2 Bridge Incheon is a proud Gold Sponsor of RESI Boston 2022, and we are excited to showcase 7 promising early-stage companies representing a wide variety of life science & healthcare technologies.
Message the company or request a 1:1 meeting here.
Series B, #Biotech #Pharmaceuticals #DryEyeDisease #ChronicPain #AMD
RudaCure is a clinical bio-pharmaceutical company founded with the vision to solve current unmet needs for intractable and incurable diseases by developing innovative first-in-class treatments to help suffering patients have quality and pain free lives.
Series A, #BioPharmaceuticals #Microbiome #Pharmabiotics
BioMe Inc.develops microbial therapeutics using the iMECTM platform, which allows precise screening and verification of microbes. We isolated microbes against respiratory and enteric infections, and others which are at the pre-clinical stage of development.
Pre B Bridge, #Biotech #Bacteriophages #Microbiome
Microbiotix Co., Ltd a biotech venture company derived from Yonsei University College of Medicine. We provide specialized lytic bacteriophage treatments for multi-drug resistant pathogens based upon our state-of-the art bacteriophage library
Change blood vessels of a 100-year-old man into a teenagers’ Blood vessels become stiff as they age, and this causes hypertension and cardiovascular diseases. Nitric oxide, a neurotransmitter that relaxes blood vessels is the solution we found.
Series A, #Lab Automation #Lab Robotics
ABLE Labs has developed a compact monitor-sized Liquid handling robot. It does not require a specialized engineer to operate. Researchers will now be able to focus on processing the outcome of the experiment, not handling small amounts of liquids.
Pre-series, A #Digital Healthcare #AI #Spatial Transcriptome
Portrai revolutionizes drug development processes with higher precision and effectiveness with Al and spatial transcriptomics. From target discovery to companion diagnostics, Portrai suggests deeper understanding and the best way to develop novel drugs.
Series B, #Digital Healthcare #Medical Image #Platform
Founded in 2019 in Seoul and led by researchers from Asan Medical Center and KAIST, Promedius provides medical Al solutions around the world to resolve global medical inequality through SaMD development and our cloud-based medical Al platform Aidant.